| Title |
Combined corticosteroid and long-acting beta2 -agonist in one inhaler versus placebo for chronic obstructive pulmonary disease
|
|---|---|
| Published in |
Cochrane database of systematic reviews, November 2013
|
| DOI | 10.1002/14651858.cd003794.pub4 |
| Pubmed ID | |
| Authors |
Luis Javier Nannini, Phillippa Poole, Stephen J Milan, Rebecca Holmes, Rebecca Normansell |
| Abstract |
Both long-acting beta2-agonists (LABA) and inhaled corticosteroids (ICS) have been recommended in guidelines for the treatment of chronic obstructive pulmonary disease (COPD). Their coadministration in a combination inhaler may facilitate adherence to medication regimens and improve efficacy. |
Twitter Demographics
The data shown below were collected from the profiles of 10 tweeters who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 10% |
| Unknown | 9 | 90% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 6 | 60% |
| Practitioners (doctors, other healthcare professionals) | 2 | 20% |
| Science communicators (journalists, bloggers, editors) | 1 | 10% |
| Scientists | 1 | 10% |
Mendeley readers
The data shown below were compiled from readership statistics for 344 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 3 | <1% |
| Brazil | 2 | <1% |
| Chile | 1 | <1% |
| Indonesia | 1 | <1% |
| Netherlands | 1 | <1% |
| South Africa | 1 | <1% |
| Tunisia | 1 | <1% |
| Spain | 1 | <1% |
| United States | 1 | <1% |
| Other | 0 | 0% |
| Unknown | 332 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 55 | 16% |
| Researcher | 45 | 13% |
| Student > Ph. D. Student | 33 | 10% |
| Student > Bachelor | 27 | 8% |
| Other | 24 | 7% |
| Other | 72 | 21% |
| Unknown | 88 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 150 | 44% |
| Nursing and Health Professions | 22 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 14 | 4% |
| Agricultural and Biological Sciences | 13 | 4% |
| Social Sciences | 13 | 4% |
| Other | 35 | 10% |
| Unknown | 97 | 28% |
Attention Score in Context
This research output has an Altmetric Attention Score of 16. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 December 2022.
All research outputs
#1,986,368
of 23,394,907 outputs
Outputs from Cochrane database of systematic reviews
#4,412
of 12,679 outputs
Outputs of similar age
#19,176
of 215,309 outputs
Outputs of similar age from Cochrane database of systematic reviews
#100
of 242 outputs
Altmetric has tracked 23,394,907 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 12,679 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 32.9. This one has gotten more attention than average, scoring higher than 65% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 215,309 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 91% of its contemporaries.
We're also able to compare this research output to 242 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 58% of its contemporaries.